Therapeutic | Utomilumab |
Target | TNFRSF9 |
Heavy Chain | EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS |
Light Chain | SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL |
100% seqID Fv Structure | 6a3w [Fvs: AB, DE, GH, JK], 6mi2 [Fvs: AB, DE] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6a3w [Fvs: AB, DE, GH, JK] |
100% seqID Structure | 6mi2 [Fvs: AB, DE] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | MorphoSys HuCAL Phage Display |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | Dana-Farber Cancer Institute, Immatics US, Kite Pharma, Kyowa Hakko Kirin, M. D. Anderson Cancer Center, Pfizer |
Conditions Approved | na |
Conditions Active | Breast cancer, Oropharyngeal cancer, Solid tumours, B-cell lymphoma, Diffuse large B cell lymphoma, Colorectal cancer, Follicular lymphoma, Ovarian cancer |
Conditions Discontinued | Non-Hodgkin's lymphoma |
Notes |